
VIRGINIA STATE BUDGET

2026 Special Session I

Budget Bill - HB30 (Chapter)

Bill Order » Office of Education » Item 150

George Mason University

Item 150

First Year - FY2027 Second Year - FY2028

Financial Assistance For Educational and General Services (11000)	\$343,825,000	\$343,825,000
Eminent Scholars (11001)	\$1,000,000	\$1,000,000
Sponsored Programs (11004)	\$342,825,000	\$342,825,000
Fund Sources:		
General	\$2,106,250	\$2,106,250
Higher Education Operating	\$341,718,750	\$341,718,750

Authority: Title 23.1, Chapter 15, Code of Virginia.

A. 1. Out of this appropriation, \$956,250 the first year and \$956,250 the second year from the general fund and \$5,850,000 the first year and \$5,850,000 the second year from nongeneral funds are designated to build research capacity in biomedical research and biomaterials engineering.

2. Out of this appropriation, \$750,000 the first year and \$750,000 the second year from the general fund is designated for applied research in simulation modeling and gaming.

B. Out of this appropriation, \$125,000 the first year and \$125,000 the second year from the general fund is designated for Lyme Disease research and medical test development.

C. The Higher Education Operating fund source listed in this Item is considered to be a sum sufficient appropriation, which is an estimate of funding required by the university to cover sponsored program operations.

D. Out of this appropriation, \$275,000 the first year and \$275,000 the second year from the general fund is designated for George Mason University, in collaboration with Old Dominion University, the University of Virginia, Virginia Commonwealth University, Virginia Tech-Carilion, INOVA, and Sentara Health System, to continue the Virginia Coordinated Clinical Research Network efforts to serve as a collective of institutions to conduct significant clinical trials in areas that include oncology, mental health and substance abuse. The Virginia Coordinated Clinical Research Network facilitates identifying and recruiting patients and expanding access for researchers to a clinical base thereby creating greater opportunities for grant funding and the development commercialization of breakthrough products and services.